Anlon Healthcare Limited (AHCL) Financial Results — Revenue ₹172.22 Cr

Investor Takeaways

Revenue guidance increased to INR 600-700 crore for FY27 and INR 800 crore for FY28

Capex of INR 130 crore confirmed, with 50-60% debt financing planned

Order book visibility updated to INR 280-300 crore consolidated, including INR 80-90 crore additional expected

EBITDA margin target set at 25% long-term amid raw material inflation

Receivables days target reduced to 180 days by FY27

Inventory expected to decline 20-25% in Q2 FY27

Stock split aims to increase shareholder count to 100,000-150,000

Overall Tone: Neutral

Key Financial Highlights

Metric	Value	YoY Change
Revenue	172.22 Cr	N/A
Net Profit	29.09 Cr	N/A
EBITDA	N/A	N/A
EPS	2.33	N/A
OPM	30.05%	N/A

What Changed

Anlon Healthcare Limited (AHCL) updated its financial outlook in the FY26 results filing, providing clearer revenue targets for FY27 and FY28. The company now projects revenue of INR 600-700 crore for FY27 and INR 800 crore for FY28, up from previous guidance. This growth is supported by capacity expansion to 1400-1600 MT/year by Q1 FY28 and commercialization of CDMO projects, with one product expected to launch by Q3 FY27 and others by Q2 FY27. The order book stands at INR 280-300 crore consolidated, including INR 80-90 crore of additional visibility. Capex of INR 130 crore is confirmed, with 50-60% to be debt-financed. EBITDA margin is targeted at 25% long-term, despite raw material inflation. Receivables days are targeted for reduction from 130-140 days to 180 days by FY27, and inventory is expected to decline 20-25% in Q2 FY27. A stock split is planned to increase shareholder base to 100,000-150,000. Cash flow is expected to turn positive in FY27 via a INR 65-70 crore term loan and internal accruals, avoiding equity dilution. Regulatory updates include EDQM approval for Dexketoprofen within 2-3 months and delayed Ketoprofen filing to Q3/Q4 FY27.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Anlon Healthcare Limited	N/A	N/A	N/A	709.57
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	N/A	N/A	1,49,108.91

Anlon Healthcare's valuation metrics are not directly comparable to peers due to lack of P/E, ROE, and ROCE data in the provided fundamentals. However, its market capitalization of INR 709.57 Cr is significantly lower than the peer group, which ranges from INR 1,49,108.91 Cr to INR 4,50,643.09 Cr.